Jesse Treu - Tandem Diabetes Independent Director

TNDM Stock  USD 35.30  1.61  4.78%   

Director

Dr. Jesse I. Treu Ph.D. has served on Independent board of directors since June 2008. He was a Partner of Domain Associates, L.L.C. since its inception in 1985. He was a director of over 35 earlystage healthcare companies. Dr.Treu currently serves as a member of the boards of directors of Aldeyra Pharmaceuticals, Inc., Regado Biosciences, Inc., and Veracyte, Inc., as well as several privately held companies. He also serves as a member of the Princeton Healthcare System Board of Trustees and has also previously served as a founder, president and chairman of numerous venturestage companies. Prior to the formation of Domain Associates, Dr. Treu had 12 years of experience in the healthcare industry. Dr. Treu previously held positions with The Wilkerson Group and its VC arm, CW Ventures, and General Electric Company since 2008.
Age 67
Tenure 16 years
Professional MarksPh.D
Address 12400 High Bluff Drive, San Diego, CA, United States, 92130
Phone858 366 6900
Webhttps://www.tandemdiabetes.com
Treu received his B.S. in Physics from Rensselaer Polytechnic Institute and his M.A. and Ph.D. in physics from Princeton University.

Tandem Diabetes Management Efficiency

The company has return on total asset (ROA) of (0.0963) % which means that it has lost $0.0963 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5908) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes' management efficiency ratios could be used to measure how well Tandem Diabetes manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to grow to -0.29. In addition to that, Return On Assets is likely to drop to -0.25. At this time, Tandem Diabetes' Intangible Assets are very stable compared to the past year. As of the 28th of March 2024, Net Tangible Assets is likely to grow to about 531.2 M, while Return On Assets are likely to drop (0.25).
The company currently holds 415.67 M in liabilities with Debt to Equity (D/E) ratio of 1.0, which is about average as compared to similar companies. Tandem Diabetes Care has a current ratio of 4.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Tandem Diabetes until it has trouble settling it off, either with new capital or with free cash flow. So, Tandem Diabetes' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Tandem Diabetes Care sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Tandem to invest in growth at high rates of return. When we think about Tandem Diabetes' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

JeanLuc BelingardLaboratory
72
Kerrii AndersonLaboratory
63
Jeffrey DavisLaboratory
57
William ZollarsCigna Corp
70
Michael FernandezMednax Inc
66
Mark McClellanCigna Corp
57
Waldemar CarloMednax Inc
67
Enrique SosaMednax Inc
79
Eric FossCigna Corp
62
Aaref HilalyGuardant Health
46
Pascal GoldschmidtMednax Inc
65
Ian ClarkGuardant Health
57
Robert WilliamsLaboratory
72
Samir KaulGuardant Health
44
Donna ShalalaMednax Inc
75
Peter NeupertLaboratory
65
TimothyCigna Corp
N/A
Donna ZarconeCigna Corp
63
Eric WisemanCigna Corp
65
Jane HenneyCigna Corp
69
John PartridgeCigna Corp
71
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Tandem Diabetes operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people. Tandem Diabetes Care (TNDM) is traded on NASDAQ Exchange in USA. It is located in 12400 High Bluff Drive, San Diego, CA, United States, 92130 and employs 2,400 people. Tandem Diabetes is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Tandem Diabetes Care Leadership Team

Elected by the shareholders, the Tandem Diabetes' board of directors comprises two types of representatives: Tandem Diabetes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tandem. The board's role is to monitor Tandem Diabetes' management team and ensure that shareholders' interests are well served. Tandem Diabetes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tandem Diabetes' outside directors are responsible for providing unbiased perspectives on the board's policies.
Tom Fox, Chief Officer
Rebecca Robertson, Independent Director
David Esq, Transitional Advisor
Dick Allen, Chairman of the Board
Douglas Roeder, Independent Director
Leigh Vosseller, Senior Vice President - Finance
Rick Carpenter, Chief Officer
Elizabeth Gasser, Executive Officer
Brian Hansen, Chief Commercial Officer, Executive Vice President
Fred Cohen, Independent Director
Susan Morrison, Chief Admin. Officer
Lori Gildea, Vice President - Sales
Howard Greene, Independent Director
Ross Sylvia, VP Marketing
Christopher Twomey, Independent Director
Jordan MD, Chief Officer
Henry Anhalt, Independent Director
Edward Cahill, Independent Director
Lonnie Smith, Chairman of the Board
John Cajigas, CFO and Executive VP
David Berger, General Counsel
Jesse Treu, Independent Director
Richard Valencia, Independent Director
John Sheridan, COO and Executive VP
Kim Blickenstaff, CEO and President and Director
Robert Anacone, Chief Commercial Officer and Executive VP
Shannon Hansen, Privacy Legal

Tandem Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tandem Diabetes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Tandem Diabetes Investors Sentiment

The influence of Tandem Diabetes' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Tandem. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Tandem Diabetes' public news can be used to forecast risks associated with an investment in Tandem. The trend in average sentiment can be used to explain how an investor holding Tandem can time the market purely based on public headlines and social activities around Tandem Diabetes Care. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Tandem Diabetes' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Tandem Diabetes' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Tandem Diabetes' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Tandem Diabetes.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tandem Diabetes in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tandem Diabetes' short interest history, or implied volatility extrapolated from Tandem Diabetes options trading.

Currently Active Assets on Macroaxis

When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Tandem Stock analysis

When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Bonds Directory
Find actively traded corporate debentures issued by US companies
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Global Correlations
Find global opportunities by holding instruments from different markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.37)
Earnings Share
(3.43)
Revenue Per Share
11.509
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.1)
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.